Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted) (2019 - 2026)
Summit Therapeutics (SMMT) reported EPS (Weighted Average and Diluted) of -$0.24 for Q1 2026, down 166.67% on a YoY basis from $0.36 in Q1 2025, and up 14.29% quarter-over-quarter from -$0.28 in Q4 2025.
Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Summit Therapeutics has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$0.24 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 166.67% year-over-year to -$0.24; the trailing twelve-month figure through Mar 2026 stood at -$1.59 (down 354.29% YoY), and the FY2025 full-year result was -$1.44, down 364.52% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.24, up from -$0.28 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.01 in Q4 2023, with the low at -$1.43 in Q1 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.23 across 5 years, with a median of -$0.09 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) plunged 853.33% — and 2024, when it jumped 95.8%.
- Summit Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.04 in 2022, then surged by 75.0% to -$0.01 in 2023, then sank by 800.0% to -$0.09 in 2024, then plunged by 211.11% to -$0.28 in 2025, then advanced by 14.29% to -$0.24 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.24 (Q1 2026), -$0.28 (Q4 2025), and -$0.31 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | -0.24 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.24 |
| Dec 31, 2025 | -0.28 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | -0.09 |
| Dec 31, 2024 | -0.09 |
| Sep 30, 2024 | -0.08 |
| Jun 30, 2024 | -0.09 |
| Mar 31, 2024 | -0.06 |
| Dec 31, 2023 | -0.01 |
| Sep 30, 2023 | -0.03 |
| Jun 30, 2023 | -0.02 |
| Mar 31, 2023 | -1.43 |
| Dec 31, 2022 | -0.04 |
| Sep 30, 2022 | -0.10 |
| Jun 30, 2022 | -0.12 |
| Mar 31, 2022 | -0.15 |
| Dec 31, 2021 | -0.21 |
| Sep 30, 2021 | -0.20 |
| Jun 30, 2021 | -0.27 |